|
Jun 3
|
ASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid further positive data
|
|
Jun 2
|
Why Genmab Stock Smashed It on Monday
|
|
Jun 2
|
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
|
|
May 27
|
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference
|
|
May 23
|
Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025
|
|
May 22
|
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
May 21
|
Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference
|
|
Apr 16
|
GMAB or RGEN: Which Is the Better Value Stock Right Now?
|
|
Apr 16
|
Should Value Investors Buy Genmab (GMAB) Stock?
|
|
Apr 15
|
Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025
|
|
Apr 15
|
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
|
|
Apr 14
|
Transactions in Connection with Share Buy-back Program
|
|
Feb 13
|
Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today
|
|
Feb 13
|
Notice to Convene the Annual General Meeting of Genmab A/S
|
|
Feb 13
|
Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
|
|
Feb 12
|
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
|
|
Feb 12
|
Genmab Publishes 2024 Annual Report
|
|
Jan 3
|
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|